Parkinsonism induced by atypical neuroleptics in a patient with severe iron deficiency.
Although still controversial, iron deficiency has been indicated as one of the risk factors for developing neuroleptic-induced extrapyramidal symptoms (EPSs), including akathisia, dystonia, and neuroleptic malignant syndrome. Here we report our experience of iron supplementation and alternating neuroleptics for treating Parkinsonism in a schizophrenic female patient having severe iron deficient anemia.
Yoshida
Takeshi
T
Suzuki
Go
G
Nibuya
Masashi
M
Sano
Shin-ya
SY
Nomura
Soichiro
S
D000293:Adolescent; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003987:Dibenzothiazepines / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007501:Iron / Q000627:therapeutic use; D000090463:Iron Deficiencies; D010302:Parkinson Disease, Secondary / Q000188:drug therapy / Q000209:etiology*; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000150:complications*; D012702:Serotonin Antagonists / Q000009:adverse effects*; D012720:Severity of Illness Index
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D012702:Serotonin Antagonists; D000069348:Quetiapine Fumarate; D007501:Iron